APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.
Journal
Hepatology international
Journal Volume
18
Journal Issue
6
Start Page
1661
End Page
1683
ISSN
1936-0541
Date Issued
2024-12
Author(s)
Lau, George
Obi, Shuntaro
Zhou, Jian
Tateishi, Ryosuke
Qin, Shukui
Zhao, Haitao
Otsuka, Motoyuki
Ogasawara, Sadahisa
George, Jacob
Chow, Pierce K H
Cai, Jianqiang
Shiina, Shuichiro
Kato, Naoya
Yokosuka, Osamu
Oura, Kyoko
Yau, Thomas
Chan, Stephen L
Kuang, Ming
Ueno, Yoshiyuki
Chen, Minshan
Cheng, Gregory
Chuang, Wan-Long
Baatarkhuu, Oidov
Bi, Feng
Dan, Yock Young
Gani, Rino A
Tanaka, Atsushi
Jafri, Wasim
Jia, Ji-Dong
Hasegawa, Kiyoshi
Lau, Patrick
Lee, Jeong Min
Liang, Jun
Liu, Zhenwen
Lu, Yinying
Pan, Hongming
Payawal, Diana A
Rahman, Salimur
Seong, Jinsil
Shen, Feng
Shiha, Gamal
Song, Tianqiang
Sun, Hui-Chuan
Masaki, Tsutomu
Sirachainan, Ekaphop
Wei, Lai
Yang, Jin Mo
Sallano, Jose D
Zhang, Yanqiao
Tanwandee, Tawesak
Dokmeci, AKadir
Zheng, Shu-Sen
Fan, Jia
Fan, Sheung-Tat
Sarin, Shiv Kumar
Omata, Masao
Abstract
In Asia-Pacific region, hepatocellular carcinoma is a serious health threat attributing to over 600,000 deaths each year and account for over 70% of global cases. Clinically, the major unmet needs are recurrence after curative-intent surgery, liver transplantation or local ablation and disease progression in those with hepatocellular carcinoma not eligible for resection or failed locoregional therapy. In the recent few years, new targeted therapy and immune-checkpoint inhibitors have been registered as systemic therapy to address these issues. Notably, new forms of systemic therapy, either as first-line or second-line therapy for unresectable hepatocellular or those not eligible for locoregional therapy, are now available. New data is also emerging with the use of systemic therapy to prevent hepatocellular carcinoma recurrence after curative-intent resection or local ablation therapy and to retard disease progression after locoregional therapy. In the future, further implementation of immune-checkpoint inhibitors and other forms of immunotherapy are expected to bring a new paradigm to the management of hepatocellular carcinoma. New insight related to immune-related adverse events with the use of immunotherapy has allso enabled optimization of the therapeutic approach to patients with hepatocellular carcinoma. The purpose of this clinical practice guideline is to provide an up-to-date recommendation based on clinical evidence and experience from expert Asia-Pacific key opinion leaders in the field of hepatocellular carcinoma. Three key questions will be addressed, namely: (1) Which patients with hepatocellular carcinoma should be considered for systemic therapy? (2) Which systemic therapy should be used? (3) How should a patient planned for immune checkpoint-based systemic therapy be managed and monitored?
Subjects
Guidelines
Hepatocellular carcinoma
Systemic therapy
The Asian Pacific Association for the study of the liver
SDGs
Type
journal article